Botulinum Toxin and Mesotherapy on Enhancement of Facial Scarring
NCT ID: NCT06562023
Last Updated: 2024-08-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
33 participants
INTERVENTIONAL
2022-11-19
2024-07-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Efficacy and Safety of Microneedling Combined With Botulinum Toxin-A Versus Meso-Botox Injection in the Treatment of Atrophic Acne Scars: A Split-face Comparative Study
NCT06544993
Microneedle Patch With Botulinum Toxin in Management of Enlarged Facial Pores
NCT06293755
Subcision Followed by Diluted Calcium Hydroxylapatite Injection Versus Subcision Followed by Painting CROSS TCA Technique for the Treatment of Atrophic Acne Scars
NCT07028567
Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation
NCT06385171
Subcision With PRP and Microneedling Versus Subcision With Saline and Micro-needling in Treatment of Posttraumatic Scars
NCT06135480
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BTA injection
Botulinum Toxin Type A
Patients will receive BTA injection within a period of 5 days after primary closure.
Mesotherapy
Mesotherapy
Patients will receive mesotherapy growth factor serum with a derma pen within a period of 5 days after primary closure.
Control
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Botulinum Toxin Type A
Patients will receive BTA injection within a period of 5 days after primary closure.
Mesotherapy
Patients will receive mesotherapy growth factor serum with a derma pen within a period of 5 days after primary closure.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Recent and fresh wounds.
* Atrophic scar (linear scar).
Exclusion Criteria
* Patient on chemotherapy treatment and history of malignancy.
* Patients suffering from burns on the forehead or complicated lacerations.
* Allergy to drugs used in this study
20 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hams Hamed Abdelrahman
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hams Hamed Abdelrahman
Assistant Lecturer of Dental Public Health and biostatistical consultanat
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Outpatient Clinic of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Alexandria University
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0926-5/2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.